Idera Pharmaceuticals (IDRA) 4.69 $IDRA
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 3:15PM CST
Idera Pharmaceuticals (IDRA) announced that the FDA has granted orphan drug designation to IMO-8400.
JNJ: 103.28 (-0.51), PCYC: 119.85 (-0.12), IDRA: 4.69 (-0.22), AFFX: 9.94 (-0.05)
Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today
at The Street - Tue Dec 30, 9:02AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.69 (-0.22)
Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno
PR Newswire - Tue Dec 30, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADXS: 7.99 (-0.68), IDRA: 4.69 (-0.22), ABEV: 6.06 (+0.22), JUNO: 51.66 (+5.71), QVCB: 29.69 (-0.62), QVCA: 27.60 (-0.51)
Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
GlobeNewswire - Tue Dec 30, 7:01AM CST
- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenstrom's macroglobulinemia
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment
at The Street - Mon Dec 29, 3:06PM CST
Shares of Idera Pharmaceuticals (IDRA) surged more than 15% in late afternoon trading on Monday after the FDA granted orphan designation to the company's treatment of Waldenstrom's macroglobulinemia.
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals Going Into 2015
Samreen Agha - at Seeking Alpha - Mon Dec 22, 1:57PM CST
IDRA: 4.69 (-0.22)
Piper Jaffray picks for 2015
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:38AM CST
BDX: 140.45 (-0.27), IDRA: 4.69 (-0.22)
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Dec 16, 8:45AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
IDRA: 4.69 (-0.22)
InsiderInsights.com Daily Round Up 12/15/14: NS, FCX, LJPC, OAS
InsiderInsights - at Seeking Alpha - Tue Dec 16, 2:28AM CST
VR: 40.11 (-0.18), GMCR: 127.19 (-2.53), LJPC: 16.84 (-0.95), FCX: 22.53 (+0.38), NS: 55.53 (-1.64), OSIS: 68.17 (-1.18), SNI: 72.75 (-1.48), GOOG: 501.96 (-11.91), HAIN: 55.08 (-0.46), WIW: 11.40 (-0.01), IDRA: 4.69 (-0.22), VRNS: 29.96 (-1.78), WRLD: 77.59 (-0.55), SNPS: 42.16 (-0.38), AI: 26.17 (-0.45), JGW: 9.62 (-0.18), OAS: 14.76 (-0.67), WIA: 11.64 (unch), CRM: 57.20 (-0.97)
Idera Announces Several Key Additions to Management Team
GlobeNewswire - Mon Dec 15, 8:06AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed J. Peter Wolf as Senior Vice President, General Counsel and Elizabeth Eberhardt as Vice President, Oncology Team.
IDRA: 4.69 (-0.22)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 17.20 (-0.28), BIIB: 334.65 (-2.09), IMMU: 4.71 (-0.28), RDHL: 14.14 (-0.93), AMGN: 152.90 (-5.09), LLY: 69.72 (+0.35), GSK: 41.68 (-0.23), ARGS: 9.51 (-0.52), NVO: 41.90 (-0.51), IDRA: 4.69 (-0.22), ANTH: 2.20 (-0.07), MRK: 60.32 (+2.28), CBMG: 13.99 (+0.83), CELGZ: 3.16 (+0.02)
Idera Pharmaceuticals Down 6.1%, Shares Slide into the Red (IDRA)
Comtex SmarTrend(R) - Tue Dec 09, 11:38AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 6.1% to $4.14 on 1.9x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.6 million shares, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-6.1% to the Dow's -0.9%) and underperformed the S&P 500 (-6.1% to the S&P's -0.8%) during today's trading.
IDRA: 4.69 (-0.22)
Idera +6.3% AH after presenting IMO-8400 data
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 6:02PM CST
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
GlobeNewswire - Mon Dec 08, 4:46PM CST
- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials
IDRA: 4.69 (-0.22)
The Biggest Risks For Stocks In 2015?
Leo Kolivakis - Seeking Alpha - Fri Dec 05, 3:07PM CST
Jeff Reeves, editor of InvestorPlace.com, wrote an article for MarketWatch, 10 biggest risks to the stock market in 2015 : It is shaping up to be another great year for stocks, with the S&P 500 up about 12% year-to-date in 2014 after a roughly...
KO: 42.46 (+0.32), XLB: 46.99 (-0.42), XBI: 184.30 (-4.70), IBB: 300.81 (-5.04), TLT: 131.65 (+2.33), GSG: 20.28 (-0.34), VOO: 183.27 (-1.82), PGNX: 6.91 (-0.35), IDRA: 4.69 (-0.22), QQQ: 100.07 (-1.36), XLK: 40.15 (-0.49), IWM: 115.31 (-2.03), CL: 67.81 (-0.72), XLE: 75.12 (-1.12)
Hawaiian Electric and Taser are big market movers
AP - Thu Dec 04, 3:35PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 211.28 (+1.19), HE: 33.25 (-0.12), PLUG: 3.05 (+0.04), CLV: 6.19 (-0.15), CLF: 6.31 (-0.21), BKS: 23.03 (-0.63), ARO: 2.24 (-0.06), RAD: 7.71 (+0.19), CARB: 13.96 (-0.07), SQNM: 3.65 (-0.06), ENB.TO: 56.01 (-2.10), RIG: 16.46 (-0.38), IDRA: 4.69 (-0.22), ANF: 28.88 (+0.61), ENB: 47.35 (-2.06), TASR: 25.57 (-0.12), AVGO: 96.25 (-2.24), PBYI: 188.12 (-0.25)
Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 7.0% (IDRA)
Comtex SmarTrend(R) - Wed Dec 03, 10:36AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 7.0% to $3.83 on 3.7x average daily volume. Idera Pharmaceuticals has traded 2.7 million shares thus far today, vs. average volume of 727,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.1%) and outperformed the S&P 500 (7.0% to the S&P's 0.2%) during today's trading.
IDRA: 4.69 (-0.22)
Idera up on preclinical data
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 9:47AM CST
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
GlobeNewswire - Tue Dec 02, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. IMO-2055 is a synthetic oligonucleotide-based agonist of Toll-like receptor (TLR) 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The data were presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting in Orlando, Fla., earlier today.
IDRA: 4.69 (-0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST
CY: 13.69 (-0.53), QDEL: 28.03 (-0.07), WLT: 1.28 (-0.09), VNCE: 22.76 (-1.50), ISNS: 2.49 (-0.14), VII: 1.71 (-0.04), NTLS: 4.20 (+0.05), MFRM: 58.82 (-1.24), GSAT: 2.49 (-0.11), MOLG: 2.92 (-0.07), EVOK: 6.48 (+0.43), IDRA: 4.69 (-0.22), SCVL: 24.11 (-0.69), VGGL: 3.21 (+0.02), MIXT: 6.33 (-0.14), ENVI: 1.53 (+0.16), REI: 9.66 (-0.48), TRX: 0.63 (+0.02), DGLY: 14.61 (-0.54), CODE: 32.65 (-1.36)
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 3:15PM CST
Idera Pharmaceuticals (IDRA) announced that the FDA has granted orphan drug designation to IMO-8400.
JNJ: 103.28 (-0.51), PCYC: 119.85 (-0.12), IDRA: 4.69 (-0.22), AFFX: 9.94 (-0.05)
Idera Pharmaceuticals (IDRA) Is Strong On High Volume Today
at The Street - Tue Dec 30, 9:02AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a strong on high relative volume candidate
IDRA: 4.69 (-0.22)
Equities in the 'Sweet Spot', Spot the Potential: Research Reports on Ambev, Liberty Interactive, Idera, Advaxis, and Juno
PR Newswire - Tue Dec 30, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Ambev (NYSE: ABEV), Liberty Interactive (NASDAQ: QVCA), Idera (NASDAQ: IDRA) Advaxis (NASDAQ: ADXS), and Juno (NASDAQ: JUNO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ADXS: 7.99 (-0.68), IDRA: 4.69 (-0.22), ABEV: 6.06 (+0.22), JUNO: 51.66 (+5.71), QVCB: 29.69 (-0.62), QVCA: 27.60 (-0.51)
Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia
GlobeNewswire - Tue Dec 30, 7:01AM CST
- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenstrom's macroglobulinemia
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals (IDRA) Stock Surges After FDA Grants Orphan Designation for Cancer Treatment
at The Street - Mon Dec 29, 3:06PM CST
Shares of Idera Pharmaceuticals (IDRA) surged more than 15% in late afternoon trading on Monday after the FDA granted orphan designation to the company's treatment of Waldenstrom's macroglobulinemia.
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals Going Into 2015
Samreen Agha - at Seeking Alpha - Mon Dec 22, 1:57PM CST
IDRA: 4.69 (-0.22)
Piper Jaffray picks for 2015
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:38AM CST
BDX: 140.45 (-0.27), IDRA: 4.69 (-0.22)
Idera Pharmaceuticals (IDRA) Marked As A Dead Cat Bounce Stock
at The Street - Tue Dec 16, 8:45AM CST
Trade-Ideas LLC identified Idera Pharmaceuticals (IDRA) as a "dead cat bounce" (down big yesterday but up big today) candidate
IDRA: 4.69 (-0.22)
InsiderInsights.com Daily Round Up 12/15/14: NS, FCX, LJPC, OAS
InsiderInsights - at Seeking Alpha - Tue Dec 16, 2:28AM CST
VR: 40.11 (-0.18), GMCR: 127.19 (-2.53), LJPC: 16.84 (-0.95), FCX: 22.53 (+0.38), NS: 55.53 (-1.64), OSIS: 68.17 (-1.18), SNI: 72.75 (-1.48), GOOG: 501.96 (-11.91), HAIN: 55.08 (-0.46), WIW: 11.40 (-0.01), IDRA: 4.69 (-0.22), VRNS: 29.96 (-1.78), WRLD: 77.59 (-0.55), SNPS: 42.16 (-0.38), AI: 26.17 (-0.45), JGW: 9.62 (-0.18), OAS: 14.76 (-0.67), WIA: 11.64 (unch), CRM: 57.20 (-0.97)
Idera Announces Several Key Additions to Management Team
GlobeNewswire - Mon Dec 15, 8:06AM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare diseases, announced that it has appointed J. Peter Wolf as Senior Vice President, General Counsel and Elizabeth Eberhardt as Vice President, Oncology Team.
IDRA: 4.69 (-0.22)
Systemic Lupus Erythematosus - Pipeline Review, H2 2014
M2 - Thu Dec 11, 5:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lhg87v/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Systemic Lupus Erythematosus - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Biogen Idec - Amgen - Sanofi - Eli Lilly and Company - GlaxoSmithKline - MedImmune - Biotest - Ablynx - Novo Nordisk - Takeda Pharmaceutical Company - Eisai - Pfizer - UCB - Celgene Corporation - XTL Biopharmaceuticals - Merck - 4SC - Harbor Therapeutics - Immunomedics - Idera Pharmaceuticals - Karo Bio - Dynavax Technologies - Hansa Medical - Immupharma - Argos Therapeutics - MacroGenics - Kineta - Xencor - SBI Biotech - Invion Limited - Anthera Pharmaceuticals - SuppreMol - NasVax - Lycera - Genosco - RedHill Biopharma - National Pharmaceutical - Resolve Therapeutics - Lead Discovery Center - Genovax - MENTRIK Biotech - Avipep Pty - AbbVie - ImmuNext - Cellular Biomedicine Group - Medsenic - Azano Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/lh...emic_lupus
DVAX: 17.20 (-0.28), BIIB: 334.65 (-2.09), IMMU: 4.71 (-0.28), RDHL: 14.14 (-0.93), AMGN: 152.90 (-5.09), LLY: 69.72 (+0.35), GSK: 41.68 (-0.23), ARGS: 9.51 (-0.52), NVO: 41.90 (-0.51), IDRA: 4.69 (-0.22), ANTH: 2.20 (-0.07), MRK: 60.32 (+2.28), CBMG: 13.99 (+0.83), CELGZ: 3.16 (+0.02)
Idera Pharmaceuticals Down 6.1%, Shares Slide into the Red (IDRA)
Comtex SmarTrend(R) - Tue Dec 09, 11:38AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's worst performing low-priced stocks, down 6.1% to $4.14 on 1.9x average daily volume. Thus far today, Idera Pharmaceuticals has traded 2.6 million shares, vs. average volume of 1.4 million shares per day. The stock has underperformed the Dow (-6.1% to the Dow's -0.9%) and underperformed the S&P 500 (-6.1% to the S&P's -0.8%) during today's trading.
IDRA: 4.69 (-0.22)
Idera +6.3% AH after presenting IMO-8400 data
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 6:02PM CST
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting
GlobeNewswire - Mon Dec 08, 4:46PM CST
- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials
IDRA: 4.69 (-0.22)
The Biggest Risks For Stocks In 2015?
Leo Kolivakis - Seeking Alpha - Fri Dec 05, 3:07PM CST
Jeff Reeves, editor of InvestorPlace.com, wrote an article for MarketWatch, 10 biggest risks to the stock market in 2015 : It is shaping up to be another great year for stocks, with the S&P 500 up about 12% year-to-date in 2014 after a roughly...
KO: 42.46 (+0.32), XLB: 46.99 (-0.42), XBI: 184.30 (-4.70), IBB: 300.81 (-5.04), TLT: 131.65 (+2.33), GSG: 20.28 (-0.34), VOO: 183.27 (-1.82), PGNX: 6.91 (-0.35), IDRA: 4.69 (-0.22), QQQ: 100.07 (-1.36), XLK: 40.15 (-0.49), IWM: 115.31 (-2.03), CL: 67.81 (-0.72), XLE: 75.12 (-1.12)
Hawaiian Electric and Taser are big market movers
AP - Thu Dec 04, 3:35PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 211.28 (+1.19), HE: 33.25 (-0.12), PLUG: 3.05 (+0.04), CLV: 6.19 (-0.15), CLF: 6.31 (-0.21), BKS: 23.03 (-0.63), ARO: 2.24 (-0.06), RAD: 7.71 (+0.19), CARB: 13.96 (-0.07), SQNM: 3.65 (-0.06), ENB.TO: 56.01 (-2.10), RIG: 16.46 (-0.38), IDRA: 4.69 (-0.22), ANF: 28.88 (+0.61), ENB: 47.35 (-2.06), TASR: 25.57 (-0.12), AVGO: 96.25 (-2.24), PBYI: 188.12 (-0.25)
Traders Get Bullish on Shares of Idera Pharmaceuticals, Shares Up 7.0% (IDRA)
Comtex SmarTrend(R) - Wed Dec 03, 10:36AM CST
Idera Pharmaceuticals (NASDAQ:IDRA) is one of today's best performing low-priced stocks, up 7.0% to $3.83 on 3.7x average daily volume. Idera Pharmaceuticals has traded 2.7 million shares thus far today, vs. average volume of 727,000 shares per day. The stock has outperformed the Dow (7.0% to the Dow's 0.1%) and outperformed the S&P 500 (7.0% to the S&P's 0.2%) during today's trading.
IDRA: 4.69 (-0.22)
Idera up on preclinical data
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 9:47AM CST
IDRA: 4.69 (-0.22)
Idera Pharmaceuticals Announces Cancer Immunotherapy Regimen With Intratumoral IMO-2055 Demonstrated Potent and Systemic Anti-Tumor Activity in Preclinical Models
GlobeNewswire - Tue Dec 02, 3:30PM CST
Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. IMO-2055 is a synthetic oligonucleotide-based agonist of Toll-like receptor (TLR) 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The data were presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting in Orlando, Fla., earlier today.
IDRA: 4.69 (-0.22)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 11:47AM CST
CY: 13.69 (-0.53), QDEL: 28.03 (-0.07), WLT: 1.28 (-0.09), VNCE: 22.76 (-1.50), ISNS: 2.49 (-0.14), VII: 1.71 (-0.04), NTLS: 4.20 (+0.05), MFRM: 58.82 (-1.24), GSAT: 2.49 (-0.11), MOLG: 2.92 (-0.07), EVOK: 6.48 (+0.43), IDRA: 4.69 (-0.22), SCVL: 24.11 (-0.69), VGGL: 3.21 (+0.02), MIXT: 6.33 (-0.14), ENVI: 1.53 (+0.16), REI: 9.66 (-0.48), TRX: 0.63 (+0.02), DGLY: 14.61 (-0.54), CODE: 32.65 (-1.36)
